December 11, 2023 02:14 PM EST
Pharma
Law

J&J ac­cused of de­fraud­ing US Patent Of­fice in an­ti-com­pe­ti­tion law­suit

Nicole DeFeudis

Editor

A group of pay­ers has ac­cused John­son & John­son of de­fraud­ing the US Patent and Trade­mark Of­fice in a scheme to curb Ste­lara com­pe­ti­tion, ac­cord­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

A service from the Financial Times